- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06524011
Stromal Vascular Fraction Enriched PRP in Treatment of Post-acne Scars
July 24, 2024 updated by: Mona El Radi Kamal Mohamed Emam, Zagazig University
Split Face Comparative Study of Stromal Vascular Fraction Enriched PRP Versus Each Alone in Treatment of Atrophic Post-acne Scars
in a split face fashion, 30 patients will be randomized into 3 groups: Group A: rt side treated with SVF enriched PRP, lt side treated with prp Group B: rt side treated with SVF enriched PRP, lt side treated with SVF Group C: rt side treated with PRP, lt side treated with SVF
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zagazig, Egypt
- Zagazig university hospitals
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- patients with atrophic post acne scars without any previous treatment trials.
- adequate blood picture, no anemia, no bleeding or platelet disorders.
Exclusion Criteria:
- pregnant and lactating females.
- elderly.
- patients with bleeding tendencies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: SVF enriched PRP vs PRP
|
Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
|
|
Active Comparator: SVF enriched PRP vs SVF
|
Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
|
|
Active Comparator: PRP vs SVF
|
Adipose derived stromal vascular fraction cells will be aspirated and isolated from patient autologous adipose tissue and used to enrich patient's autologous platelet rich plasma then will be used to treat atrophic post acne scars versus each alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in severity of acne scars using Goodman scoring system
Time Frame: 3 monthly sessions and follow up for 3 months after the last visit
|
at baseline, acne scars will be assessed clinically using the 4 point grading system proposed by Goodman &colleagues in 2006, patients' complaints and expectations will be addressed as well and the impact of acne scars on patients' quality of life will be investigated using the dermatology life quality index (DLQI).
Goodman scoring system will be used at the last session and at the follow up visit to measure the change pre and post treatment.
|
3 monthly sessions and follow up for 3 months after the last visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
October 6, 2023
First Submitted That Met QC Criteria
July 24, 2024
First Posted (Actual)
July 29, 2024
Study Record Updates
Last Update Posted (Actual)
July 29, 2024
Last Update Submitted That Met QC Criteria
July 24, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Dr. MonaRadi
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Scars - Atrophic
-
CLASSYS Inc.Not yet recruitingAcne Scars | Acne Scarring | Acne Scar | Acne Scars - AtrophicChina
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedAcne Scar | Acne Scars - AtrophicChina
-
Assiut UniversityNot yet recruiting
-
Ngô Anh TuấnCompletedAtrophic Acne ScarsVietnam
-
Cairo UniversityRecruiting
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityCompletedWound Healing | Acne Scars - AtrophicChina
-
Ulthera, IncCompleted
-
Seoul National University HospitalNot yet recruitingAcne Scars | Acne Scars - Atrophic
-
Gujranwala medical college District Headquarters...Saglik Bilimleri UniversitesiRecruitingPlatelet-Rich Plasma | Post-Acne Atrophic Scars | Carbon Dioxide LasersPakistan
-
Suneva Medical, Inc.ethica Clinical Research Inc.CompletedAtrophic Acne ScarsUnited States
Clinical Trials on Stromal vascular fraction (SVF) enriched platelet rich plasma (PRP) versus each alone
-
Robert W Alexander, MDRegeneris Medical; Global Alliance for Regenerative MedicineUnknownOsteoarthritis | Back Pain | Tendinopathy | Tendinosis | Degenerative Joint Disease | Rheumatoid NoduleUnited States
-
Kasr El Aini HospitalNot yet recruitingAndrogenetic AlopeciaEgypt
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
University of Science Ho Chi Minh CityVan Hanh General Hospital; GeneWorld Co., Ltd., Ho Chi Minh; 115 People's HospitalCompletedAutologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee OsteoarthritisKnee OsteoarthritisVietnam